Article
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Chest - 1 Nov 2022
Sato Yuki, Sumikawa Hiromitsu, Shibaki Ryota, Morimoto Takeshi, Sakata Yoshihiko, Oya Yuko, Tamiya Motohiro, Suzuki Hidekazu, Matsumoto Hirotaka, Yokoi Takashi, Hashimoto Kazuki, Kobe Hiroshi, Hino Aoi, Inaba Megumi, Tsukita Yoko, Ikeda Hideki, Arai Daisuke, Maruyama Hirotaka, Hara Satoshi, Tsumura Shinsuke, Sakata Shinya, Fujimoto Daichi
Abstract excerpt
BACKGROUND: Osimertinib has demonstrated impressive efficacy as a first-line treatment for patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung cancer. Drug-related pneumonitis (DRP) is a potentially lethal complication of osimertinib treatment, but reliable real-world data currently are lacking. RESEARCH QUESTION: What is the prevalence of osimertinib-induced DRP in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.